跳至主要内容
临床试验/NCT00889668
NCT00889668Unknown1 期

Evaluation of the Performance and Use of GlucoTrack Model DF-F Non-Invasive Glucose Monitoring Device.

Integrity Applications Ltd.2 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2009年5月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
发起方
入组人数
180
试验地点
2
主要终点
Clarke Error Grid

研究概览

简要总结

Diabetes is a leading cause of death in the Western World with medical costs increasing annually. There is no cure for diabetes, and blood glucose monitoring is a key component in diabetes treatment and management. Self-monitoring of blood glucose levels is essential to the self-management of diabetes and has become widespread over the past decade. Blood glucose determinations are currently done by invasive methods (finger tip pricking), followed by measuring the blood drop characteristics.

The purpose of this trail is to demonstrate the performance and use of GlucoTrack device in measuring blood glucose levels.

The rationale for development of the device is to improve the patient's quality of life by providing a device that is easily used and provides a painless measurement method, thereby leading to higher compliance, and to better managed diabetes

详细描述

See Brief summary

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Screening
盲法
None

入排标准

年龄范围
10 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 1or 2 Diabetes
  • Anatomically suitable earlobe

排除标准

  • Subjects requiring dialysis
  • Any conditions that may hamper good contact between the PEC and the earlobe
  • Pregnancy
  • Nursing mothers

研究组 & 干预措施

Experimental

Experimental

subjects with a diagnosis of type 1 or 2 diabetes; GlucoTrack results will be compared with the readings from approved invasive glucose meter device.

干预措施: GlucoTrack (Device)

结局指标

主要结局

Clarke Error Grid

时间窗: one year

次要结局

  • User Satisfaction(one year)

研究者

发起方
Integrity Applications Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验